Background
The discovery of circulating cell-free DNA (ccfDNA) in the human circulatory system has led to intensive research on its use in various clinical fields. CcfDNA was discovered in 1948 by Mandel and Metais (1) although at the time, it did not attract much curiosity. However, 30 to 40 years later, the interest of ccfDNA was demonstrated by several groups including Leon, et al. (2) , who found that ccfDNA concentration significantly increased in cancer subjects, and Stroun, et al. (3) , who described a proportion of ccfDNA that was tumor-derived and carried its molecular characteristics, leading to the concept of a "liquid biopsy." Therefore, ccfDNA analysis could provide diagnostic, prognostic, and theragnostic information (4) (5) (6) . Several researchers are intensively developing techniques that allow detection and characterization of genetic and epigenetic alterations of tumor cells using ccfDNA analysis in the plasma or serum of cancer subjects. Such techniques could revolutionize the management of cancer-patient care through the detection of mutations leading to resistance to targeted therapies, personalized therapeutic monitoring, and non-invasive follow-up of the disease. CcfDNA analysis is currently used in prenatal diagnosis (4) and shows potential for analysis in other clinical fields, such as autoimmune diseases, trauma, sepsis, or myocardial infarction (5).
Discussion

Potential of ccfDNA analysis in oncology
Despite intensive research, few ccfDNA-based tests have been translated to clinical practice. Several techniques are under development to detect and characterize ccfDNA in cancer subjects including restriction fragment length polymorphism, direct sequencing, high-resolution melting analysis, digital PCR, cold PCR, and other techniques usually used for tumor-tissue analysis. Nevertheless, ccfDNA concentration has not yet been validated as a cancer biomarker because the literature reveals conflicting data: plasma ccfDNA concentrations in cancer subjects range from a few ng/ml to several thousand ng/ml, which overlap with the concentration range for healthy individuals (6) .
Furthermore, estimation of ccfDNA fragmentation in cancer subjects has been found to be lower (7), equivalent (8) , or higher (9-11) than in control subjects. These discrepancies may be explained by the lack of fundamental knowledge of ccfDNA. Indeed, the cognitive aspects of ccfDNA are still not identified and elucidated: the respective contributions of different potential release mechanisms of ccfDNA (apoptosis, necrosis, phagocytosis, extracellular DNA traps, active release, etc.) and the ccfDNA structures (part of chromatin, nucleosomes, nucleoprotein complex, exosomes, apoptotic bodies, etc.) have not been clearly defined (5) (6) (7) (8) (9) (10) (11) .
Total circulating DNA concentration was envisaged for long time as a potential cancer biomarker, but ccfDNA concentration values from healthy and cancer individuals have been shown to partly overlap, precluding its development for clinical use (12) (13) . Recently using current methods and a specific PCR system design, statistically significant differences in ccfDNA have been shown between healthy subjects and cancer subjects (14) .
Moreover, we revealed that circulating tumor DNA is highly fragmented compared to ccfDNA from healthy subjects. Targeting short sequences revealed that up to 50 percent of total ccfDNA could be derived from the tumor (14-15) which contradicts previous literature describing tumor-derived ccfDNA as a tiny portion of total ccfDNA (16) .
CcfDNA analysis constitutes a hopeful approach to provide a non-invasive tumor molecular test for cancer patients, especially for detecting genetic or epigenetic alterations, such as point mutations or Single Nucleotide Polymorphisms, microsatellites alterations, methylations, or Copy Number variations (12) . In particular, detecting point mutations in numerous cancer types has been investigated intensely during the last decade (17) (18) (19) .
Our Expertise on R&D on ccfDNA Analysis
Background and pioneering observations
Our group has worked since 2005 on circulating DNA and has provided pioneering observations on the structure and origins of tumor-derived ccfDNA (10, (11) (12) (13) (14) (15) . Based on these observations, we designed Intplex, an allele specific Q-PCR-based system targeting short DNA sequences specifically adapted for ccfDNA analysis. We have achieved the first clinical validation of ccfDNA analysis in oncology and confirmed the powerful biomedical potential of ccfDNA analysis (20) . This clinically validated, cost effective, rapid, and highly sensitive method enables distinctive multi-marker ccfDNA analysis, which is adapted to effective longitudinal analysis for cancer patient follow up (14) .
The IntPlex Method
Characteristics
IntPlex is an allele specific Q-PCR system with an oligoblocker using an ingenious primer design with characteristics based on previously made structural observations. IntPlex is the first multiplexed test for ccfDNA. It determines simultaneously five parameters in a single run: (i) total ccfDNA concentration, (ii) mutant (tumor) ccfDNA concentration, (iii) proportion of mutant ccfDNA, (iv) ccfDNA fragmentation index, and (v) detection of previously known point mutations.
Performance and unmet sensitivity
Intplex can be adapted to all mutations, genes, or cancers and enables rapid, highly sensitive, cost effective and repetitive analysis. Because mutant ccfDNA can be present at very low frequencies (down to 0.01 percent of total ccfDNA), sensitivity is a critical issue when analyzing ccfDNA. Intplex enables single-copy detection of variant alleles down to an unprecedented sensitivity of 0.005 percent mutant to WT ratio, which is slightly higher than that of digital PCR or BEAMing methods and much higher than sequencing (1 percent) (20) . It detects a single ccfDNA fragment under the Poisson law. The detection limit of this method is two copies/mL plasma surpassing by more than 100-fold the sensitivity of the available Next Generation Sequencing methods. Although NGS is being proposed as technical solution for detecting a large coverage of point mutation in circulating tumor-derived DNA, its sensitivity is limited only in the case of ccfDNA analysis. The Intplex success rate is 100 percent (14) (15) (16) (17) (18) (19) (20) in more than 300 stage I-IV CRC and 80 healthy individual plasma samples. Mean data turnaround time is two days.
Our goal is to offer to a maximum of cancer patients personalized medicine, not only by providing predictive information, but also follow-up, prognosis, and diagnosis. To do so, we designed a simple, rapid, repetitive, cost-effective method for ccfDNA analysis providing qualitative and quantitative information through a multi-marker strategy in a single run. The potential of the IntPlex method highlights the diagnostic power of ccfDNA.
Future Directions
Detection of point mutation from a blood test
Numerous works have reported the detection of different mutations in different genes and for different malignancies during the last decade (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) . We validated the detection of KRAS/ BRAF point mutation in 106 clinical samples from mCRC patients with 98 percent specificity by tumor-tissue analysis in a blinded multicenter clinical study, thus demonstrating the first clinical validation of ccfDNA analysis in oncology (20) . Optimal achievement of this goal is limited by the very low level of mutation allele frequency in some plasma samples, which requires a very sensitive detection method, and the paucity of the number of ccfDNA molecules in blood, which can be as low as 2 molecules/L blood, implying a powerful extraction method.
Multi-marker approach for ccfDNA analysis
Detecting only genetic alterations by ccfDNA analysis is rather restrictive; we believe that quantitative analysis is of high interest because it increases the power of ccfDNA analysis and consequently leads to personalized medicine. In addition to the detection of a previously known point mutation, IntPlex determines simultaneously four other quantitative parameters (14): (i) total ccfDNA concentration, (ii) mutant (tumor) ccfDNA concentration, (iii) proportion of mutant ccfDNA, and (iv) ccfDNA fragmentation index. Accuracy of the concentrations of these parameters has been validated experimentally (14) . Clearly, the future of ccfDNA relies in associating qualitative information (i.e. mutation detection) with quantitative information, thus affording prognostic power and cancer-patient follow up.
Prognostic power
This work was initiated by Spindler, et al. (21) who first envisaged and demonstrated this specific power. The prognostic potential of total ccfDNA concentration, (ii) mutant (tumor) ccfDNA concentration, (iii) proportion of mutant ccfDNA, and (iv) ccfDNA fragmentation index has been demonstrated in an mCRC cohort by IntPlex.
Longitudinal ccfDNA analysis for cancer-patient follow up
CcfDNA has high potential for the longitudinal examination of cancer patients in multiple indications: Diehl, et al. (17) and Dawson, et al. (18) first described the use of mutant ccfDNA to follow tumor burden after surgery or during the course of therapy; ccfDNA analysis has been proven to detect the emergence of RAS and BRAF mutations following anti-EGFR therapy in mCRC patients by longitudinal analysis (data not shown).
Early detection of drug resistance by detecting the emergence of mutations
Tumor progression is characterized by the acquisition of distinct somatic mutations: drivers, associated with clonal expansion, and passengers, selectively neutral, that are found in clonal linkage with the driver (22, 23) .Tumor heterogeneity represents a major issue, as the emergence of mutant subclones resistant to targeted therapy negatively affects the clinical outcome for advanced cancer patients (23) .
Bardelli, et al. (23) and Diaz, et al. (24) first demonstrated capacity of ccfDNA analysis to detect mutations causing subsequent drug resistance to anti-EGFR targeted therapy by detecting RAS and EGFR mutations in mCRC plasma. Using Intplex, we demonstrated that very low allele frequency subclones initially undetected by tumor tissue sequencing caused anti-EGFR resistance and that detection of very low mutation load ccfDNA below 0.01 percent is needed to detect all of them (data not shown). Specific clinical studies are underway to validate clinically the capacity of anticipating drug resistance by ccfDNA analysis before imaging conventional standard of care.
Detection of the minimal residual disease and surveillance of recurrence
Surgery with curative intent is used for solid tumor cancer patients. A central question is whether further therapy is needed after surgical removal of the cancer. Currently, predicting which patients are disease-free after surgery (cured) and those who have residual disease depends largely on clinical and pathological parameters. There is currently no effective diagnostic means to distinguish between those patients that are disease-free and those with minimal residual disease that cannot be detected by clinical examination or imaging. Undetected, untreated minimal residual disease gives rise to recurrences. As a result, patients with high-risk clinical and pathological criteria are treated indiscriminately with adjuvant chemotherapy. Unfortunately, this therapy is frequently either unnecessary in cases where the patient would have been cured with surgery/radiotherapy alone, or ineffective in cases where the cancer is resistant to the selected adjuvant therapy or where resistance develops during the course of therapy and the cancer eventually relapses. CcfDNA analysis would have great potential in both scenarios.
Circulating mitochondrial ccfDNA
In addition to the current vigorous research on nuclear ccfDNA analysis, mitochondrial ccfDNA analysis is emerging as a very attractive study field. During tumorigenesis, because of lack of protection by histones and efficient DNA repair mechanisms, mitochondrial DNA is sensitive to genotoxic and oxidative stress (25) . In respect to tumorigenesis, mitochondrial DNA exhibits three characteristics: point mutations (10 to 200-fold higher mutation rate than nuclear DNA), CNV, and heteroplasmy (25) . These characteristics make mitochondrial ccfDNA of high interest and its analysis would undoubtedly give considerable input to personalized medicine in oncology.
